☆ 4.6 Editorial Material

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD

KIDNEY INTERNATIONAL REPORTS (2022)

Related references

Note: Only part of the references are listed.
Article Urology & Nephrology

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs

David Z. I. Cherney et al.

Summary: This study analyzed the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs), specifically semaglutide, in reducing hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes across different levels of kidney function. The results showed that semaglutide effectively reduced HbA1c levels regardless of the baseline estimated glomerular filtration rate (eGFR), and also resulted in significant weight loss.

KIDNEY INTERNATIONAL REPORTS (2022)

Add to Collection
Article Endocrinology & Metabolism

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

Cristian Guja et al.

DIABETES THERAPY (2020)

Add to Collection
Article Endocrinology & Metabolism

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection
Article Endocrinology & Metabolism

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Katherine R. Tuttle et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.